

Publisher: Karger
E-ISSN: 2296-5262|24|2|166-168
ISSN: 2296-5270
Source: Oncology Research and Treatment, Vol.24, Iss.2, 2001-05, pp. : 166-168
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma
Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. :








Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer
Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. :